Enzo Biochem Profit Margin

The latest profit margin for ENZ is -76.73% as of April 2025. That compares with 947.53% in the prior-year period — down 108.1% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Enzo Biochem's historical trend and sector peers before judging valuation or financial health.

Over the past year, ENZ's profit margin moved from 947.53% to -76.73% — a 108.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Enzo Biochem's valuation or profitability profile.

Against Healthcare companies, ENZ currently prints -76.73% for profit margin, while the sector average sits near 13.89%. That is roughly 652.3% below the sector mean. Large gaps often invite a closer look at Enzo Biochem's growth, margins, and balance sheet.

Profit Margin shows how effectively Enzo Biochem converts resources into returns. At -76.73%, ENZ may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 947.53% in the prior-year period — down 108.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ENZ's profit margin (-76.73%), review year-over-year change from 947.53%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.